Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Liposomal vitamin C delivers higher bioavailability than conventional formulations
Botanic Healthcare, manufacturer of science-backed nutraceutical ingredients, has announced the publication of clinical data demonstrating the superior bioavailability of Lipomac™, a clinically engineered liposomal vitamin C developed using patented DFS Technology.
The randomised, open-label, crossover clinical study evaluated the pharmacokinetics of Lipomac compared with conventional non-liposomal vitamin C in 12 healthy adult subjects. The results showed significantly higher systemic exposure following Lipomac supplementation, confirming enhanced absorption, improved gastrointestinal transit, and prolonged vitamin C circulation. The findings provide robust human evidence supporting Lipomac delivery as an effective strategy to overcome the inherent absorption limitations associated with conventional vitamin C formulations.
The clinical study was designed as a randomised, open-label, cross-over evaluation conducted in 12 healthy adults, directly comparing Lipomac liposomal vitamin C with standard non-liposomal vitamin C. The study demonstrated markedly higher bioavailability and systemic exposure with Lipomac, reinforcing the clinical advantages of liposomal delivery.
Lipomac is developed using Botanic Healthcare’s proprietary DFS Technology, a patented platform engineered to stabilise sensitive active ingredients, enable targeted delivery, and maximise biological performance. Lipomac is part of Lipsobio, Botanic Healthcare’s advanced portfolio of liposomal ingredients spanning vitamins, minerals, nutraceuticals, and botanical actives. Lipsobio® authenticates each ingredient through Cryo-EM/TEM imaging, nanoscale structural mapping, stability and encapsulation profiling, in-vitro absorption experiments, and clinical data, providing a scientific standard few can match.
Commenting on the findings, Dr HN Shivaprasad, Chief Scientific Officer, Botanic Healthcare, said that, “these findings validate the core scientific engineering behind DFS Technology™ and reinforce the measurable performance advantages of liposomal formats.””.
Gaurav Soni, Founder and Managing Director, stated, “Lipomac showcases the company’s commitment to clinically backed innovation and strengthens its position as a science-forward partner to global nutraceutical brands”.
Madhu Krishnamani, Founder and Managing Director, added, “The company is proud to advance health-focused solutions grounded in evidence and designed to deliver meaningful value to consumers worldwide.”